Business

RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT

Jul 12, 2025 - 22:00
 0
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT
Read More

Related Posts

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

Mar 21, 2025  0

Elon Musk says DOGE cuts necessary, but face headwinds according to Fox poll

Elon Musk says DOGE cuts necessary, but face headwinds ...

Mar 21, 2025  0

London's Heathrow Airport to reopen after fire causes power outage

London's Heathrow Airport to reopen after fire causes p...

Mar 21, 2025  3

Disney investor pledges to continue fight as shareholders reject proposal to distance company from LGBT group

Disney investor pledges to continue fight as shareholde...

Mar 21, 2025  0

Dream Finders Homes director Lovett sells $2.65 million in stock

Dream Finders Homes director Lovett sells $2.65 million...

Mar 21, 2025  0

ZipRecruiter president David Travers sells $106,161 in stock

ZipRecruiter president David Travers sells $106,161 in ...

Mar 21, 2025  0